Ribociclib Succinate
Brand name: Kisqali
Rank #172 of 500 drugs by total cost
$90.3M
Total Cost
5,978
Total Claims
$90.3M
Total Cost
331
Prescribers
$15K
Cost per Claim
38
Beneficiaries
5,989
30-Day Fills
$273K
Avg Cost/Provider
18
Avg Claims/Provider
About Ribociclib Succinate
Ribociclib Succinate (sold as Kisqali) was prescribed 5,978 times by 331 Medicare Part D providers in 2023, costing the program $90.3M. At $15K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 169 | Trazodone Hcl (Trazodone Hcl) | $92.6M | 7,273,528 |
| 170 | Insulin Glargine/Lixisenatide (Soliqua 100-33) | $92.5M | 82,886 |
| 171 | Latanoprost (Latanoprost) | $92.3M | 4,388,601 |
| 172 | Ribociclib Succinate (Kisqali) | $90.3M | 5,978 |
| 173 | Lacosamide (Lacosamide) | $90.1M | 300,038 |
| 174 | Mepolizumab (Nucala) | $90.1M | 20,798 |
| 175 | Finerenone (Kerendia) | $89.5M | 93,151 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology